33 Results for "

CYP17-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "CYP17-IN-1" in MCE Product Catalog:

Cat. No.: HY-101516
CAS No.: 2093317-51-0
Target:  

Cytochrome P450

Research Areas:  

Cancer

CYP17-IN-1 (compound 9c) is a potent and orally active CYP17 inhibitor against rat and human CYP17 with IC50s of 15.8 and 20.1 nM .
loading...
    loading...
26
26 Publications Verification
Cat. No.: HY-70013
CAS No.: 154229-19-3
Synonyms: CB-7598
Target:  

Cytochrome P450

Research Areas:  

Cancer

Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-75054
CAS No.: 154229-18-2
Synonyms: CB7630
Target:  

Cytochrome P450

Research Areas:  

Cancer

Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0105B
CAS No.: 142128-57-2
Synonyms: (-)-Ketoconazole; (-)-Ketoconazol; (-)-R 41400
Target:  

Cytochrome P450

Research Areas:  

Infection Inflammation/Immunology

Levoketoconazole ((-)-Ketoconazole) is the 2S,4R enantiomer derived from racemic Ketoconazole (HY-B0105). Levoketoconazole is a potent and orally active cortisol synthesis inhibitor. Levoketoconazole inhibits key steps in cortisol and testosterone synthesis by inhibiting CYP11B1, CYP11A1, and CYP17A1. Levoketoconazole can be used for research on endogenous Cushing’s syndrome .
loading...
    loading...
Cat. No.: HY-70013S
CAS No.: 2122245-62-7
Synonyms: CB-7598-d4
Abiraterone-d4 is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
loading...
    loading...
Cat. No.: HY-109619
CAS No.: 154229-21-7
Purity:  99.75%
Synonyms: Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite
Research Areas:  

Cancer

D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor.
loading...
    loading...
Cat. No.: HY-75054R
CAS No.: 154229-18-2
Synonyms: CB7630 (Standard)
Research Areas:  

Cancer

Abiraterone acetate (Standard) is the analytical standard of Abiraterone acetate. This product is intended for research and analytical applications. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
loading...
    loading...
Cat. No.: HY-W741510
CAS No.: 1882-82-2
Synonyms: 21-Desoxycortisone; NSC 38722
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

21-Deoxy Cortisone (21-Desoxycortisone; NSC 38722) is a corticosteroid metabolite of 11-ketoprogesterone. It is formed from 11-ketoprogesterone by the cytochrome P450 (CYP) isozyme CYP17A1, but can also be produced by oxidation of 21-deoxycortisone (HY-113405) by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). Congenital adrenal hyperplasia is an inborn error of metabolism characterized by a deficiency of 21-hydroxylase, and 21-Deoxy Cortisone levels are elevated in patients with congenital adrenal hyperplasia.
loading...
    loading...
Cat. No.: HY-148375
CAS No.: 1993430-25-3
Purity:  98.87%
Target:  

Drug Metabolite

Research Areas:  

Others

Abiraterone sulfate is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
loading...
    loading...
Cat. No.: HY-103687
CAS No.: 1940176-03-3
Purity:  99.59%
Synonyms: 3β-OH-5α-Abi
Target:  

Drug Metabolite

Research Areas:  

Cancer

Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.
loading...
    loading...
Cat. No.: HY-116643
CAS No.: 786-97-0
Target:  

Cytochrome P450

Research Areas:  

Metabolic Disease

SU 10603 is a specific inhibitor of P45017α (P450c17; CYP17A1) .
loading...
    loading...
Cat. No.: HY-137193
CAS No.: 219843-75-1
Target:  

Drug Metabolite

Research Areas:  

Cancer

5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .
loading...
    loading...
Cat. No.: HY-111421
CAS No.: 1642818-64-1
Research Areas:  

Cancer

ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC50s of 80 nM and 22 nM, respectively.
loading...
    loading...
Cat. No.: HY-175972
Target:  

Carbonic Anhydrase

Research Areas:  

Neurological Disease Cancer

CAI/II-IN-12 is a potent and hCAI (IC50 = 7.12 μM, Ki = 9.26 μM) and hCAII (IC50 = 10.62 μM, Ki = 11.72 μM) dual inhibitor. CAI/II-IN-12 has a strong affinity for the active sites of CYP17A1, hCAI, and hCAII enzymes. Compound CAI/II-IN-12 exhibits rapid conformational stabilization, particularly in the CYP17A1 complex. CAI/II-IN-12 can be used for the study of prostate cancer therapy and glaucoma .
loading...
    loading...
Cat. No.: HY-172173
Target:  

Cytochrome P450

Research Areas:  

Cancer

CYP17A1-IN-1 (Compound 14) is the inhibitor for CYP17A1 with an IC50 of 26 nM. CYP17A1-IN-1 exhibits cytotoxicity in androgen-sensitive prostate cancer cell LNCaP, inhibits the migration of cell DU-145 .
loading...
    loading...
Cat. No.: HY-163359
CAS No.: 3047489-22-2
Target:  

Cytochrome P450 HDAC

Research Areas:  

Cancer

CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC50 of 0.284μM and 0.6015 μM,respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity .
loading...
    loading...
Cat. No.: HY-117529
CAS No.: 1370001-71-0
Target:  

Cytochrome P450

Research Areas:  

Cancer

BMS-351 (compound 18) is a potent, oral active, nonsteroidal CYP17A1 lyase inhibitor with the IC50 values of 19 nM and 4 nM aganist human CYP17A1 and cynomolgus monkeys CYP17A1,respectively. BMS-351 can be used for the study of castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-RS03437
Research Areas:  

Others

CYP17A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP17A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-164457
CAS No.: 1429329-63-4
Target:  

Cytochrome P450

Research Areas:  

Cancer

ASN-001 is an orally active CYP-17A1 lyase inhibitor that selectively inhibits testosterone synthesis. ASN-001 has anticancer activity and can be used for research in the field of prostate cancer .
loading...
    loading...
Cat. No.: HY-148376
CAS No.: 2378463-76-2
Target:  

Drug Metabolite

Research Areas:  

Cancer

Abiraterone N-oxide is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
loading...
    loading...